Page last updated: 2024-10-24

candesartan and Coronary Stenosis

candesartan has been researched along with Coronary Stenosis in 2 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Coronary Stenosis: Narrowing or constriction of a coronary artery.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lee, SR1
Chae, IH1
Kim, HL1
Kang, DY1
Kim, SH1
Kim, HS1
Wakeyama, T1
Ogawa, H1
Iida, H1
Takaki, A1
Iwami, T1
Mochizuki, M1
Tanaka, T1

Trials

2 trials available for candesartan and Coronary Stenosis

ArticleYear
Predictors of candesartan's effect on vascular reactivity in patients with coronary artery disease.
    Cardiovascular therapeutics, 2017, Volume: 35, Issue:5

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Brachial Artery;

2017
Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial.
    Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:6

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Benzimidazoles; Biphenyl Co

2003